Browsing Tag
Pfizer Inc.
26 posts
Pfizer sweetens Metsera acquisition offer to secure board approval and fend off Novo Nordisk challenge
Find out how Pfizer’s amended $86.25-per-share merger with Metsera reshapes the obesity-drug race and signals Big Pharma’s shifting acquisition strategy.
Metsera picked Pfizer over Novo Nordisk — here’s what swung the $10bn deal
Pfizer secures obesity biotech Metsera for $10 billion after regulatory pushback sidelines Novo Nordisk. Find out what this means for pharma M&A now.
Pfizer Q3 2025 earnings beat forecasts as non-COVID drug sales lift margins and EPS guidance
Find out how Pfizer beat Q3 2025 earnings forecasts and raised full-year EPS guidance as non-COVID drugs and cost savings drove profit growth.
Merger war explodes: Pfizer drags Metsera and Novo Nordisk to court over ‘illegal’ bid
Pfizer takes legal action against Metsera and Novo Nordisk over breach of merger terms. Find out how this battle could reshape obesity drug M&A.
Bladder cancer breakthrough: FDA gives Priority Review to Merck’s KEYTRUDA and KEYTRUDA QLEX + PADCEV combinations
Find out how Merck’s KEYTRUDA and new KEYTRUDA QLEX + PADCEV combinations are set to transform treatment for muscle-invasive bladder cancer — read more now
Padcev and Keytruda combo cuts bladder cancer recurrence risk by 60% in pivotal Phase 3 win
Discover how the Padcev and Keytruda combination achieved unprecedented survival gains in bladder cancer — read our expert take.
Pfizer just flipped the script on drug prices—now Eli Lilly and Amgen are ripping. Is this the start of a new pharma bull run?
Pfizer’s U.S. drug-pricing pact triggers a pharma relief rally. See what it means for Eli Lilly, Amgen, and investors today—read the data-driven outlook.
Why Merck’s MSD is paying up to $600m for Evaxion’s undisclosed vaccine candidate EVX-B3
MSD licenses Evaxion’s AI-discovered vaccine EVX-B3 with $7.5M upfront and up to $592M in milestones—why this risky biotech bet could redefine vaccines.
Can Pfizer’s pipeline offset looming patent cliffs despite a stronger 2025 forecast?
Can Pfizer’s oncology and rare disease pipeline replace billions lost to patent cliffs? Explore how the drugmaker compares with Merck, Bristol Myers, and AstraZeneca.
Pfizer beats Q2 2025 earnings expectations and raises profit forecast, but long-term growth questions persist
Pfizer beats Q2 2025 estimates and raises profit guidance, but patent expirations and pricing pressures keep long-term growth questions on the table.